Old and new scoring systems for assessing cardiovascular risks: Problems with the validity, the precision and the homogenicity of the risk categories;Oude en nieuwe scoresystemen voor het schatten van cardiovasculaire risico's: Beperkingen in de validiteit, de precisie en de homogeniteit van de risicocategorieën

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 50, 2004, Pages 2480-2484

  Smulders, Y M ^a   Spijkerman, A M W ^c   Kostense, P J ^c   Bouter, L M ^c   Stehouwer, C D A ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTICAL ERROR; ARTIFACT; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; HUMAN; PREDICTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VALIDATION PROCESS;

CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 10644233121     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Rabelink TJ. Hart- en vaatziekte bij 55-plussers bestrijden met een combinatiepil legen 4 risicofactoren; kanttekeningen. Ned Tijdschr Geneeskd 2003;147:1537-8.
2. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing (CBO). Consensus 'Behandeling en preventie van coronaire hartziekte door verlaging van de plasmacholesterolconcentratie'. Tweede herziening. Utrecht: CBO; 1998.
3. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Herziene richtlijn 'Hoge bloeddruk'. Alphen aan den Rijn: Van Zuiden Communications; 2000.
4. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-503.
5. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? BMJ 1995;310:975-8.
6. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(1 Pt 2):293-8.
7. Conroy RM, Pyorälä K, Fitzgerald AP, Sans S, Menotti A, de Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe. Eur Heart J 2003;24:987-1003.
8. D'Agostino sr RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
9. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? Heart 1999;81:40-6.
10. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003;57:634-8.
11. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000;21:365-70.
12. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
13. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 2002;9:183-90.
14. Stehouwer CDA. Beleidsadviezen aan arisen en economische overwegingen daarbij; Verdiensten en bezwaren. Ned Tijdschr Geneeskd 1999;143:776-8.
15. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.
16. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). United Kingdom Prospective Diabetes Study (UKPDS) Group. Clin Sci (Colch) 2001;101:671-9.
17. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996;27: 978-90.
18. Boer JMA, Feskens EJM, Verschuren WMM, Seidell JC, Kromhout D. The joint impact of family history of myocardial infarction and other risk factors on 12-year coronary heart disease mortality. Epidemiology 1999;10:767-70.
19. Donnelly R, Yeung JM, Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens 2003;21(Suppl 1):S7-12.
20. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92:17K-22K.
21. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139(2 Pt 1):272-81.
22. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. Arterioscler Thromb Vasc Biol 1999;19:1819-24.